iBio (IBIO) Free Cash Flow (2010 - 2026)
iBio (IBIO) posted quarterly Free Cash Flow of -$6.1 million for Q1 2026, down 96.24% year-over-year from -$162.6 million in Q1 2025, and down 6.26% quarter-over-quarter from -$5.8 million in Q4 2025.
iBio (IBIO) Free Cash Flow (2010 - 2026) Analysis & Trends
iBio (IBIO) has reported Free Cash Flow for 17 consecutive years, with -$6.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 96.24% year-over-year to -$6.1 million; the TTM figure through Mar 2026 stood at -$22.2 million (down 40.44% YoY), while the FY2025 annual figure was -$15.3 million, up 18.38% from the prior year.
- Free Cash Flow declined to -$6.1 million in Q1 2026 per IBIO's latest filing, from -$5.8 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$3.1 million in Q1 2025 and bottomed at -$16.4 million in Q3 2022.
- Historically, Free Cash Flow has averaged -$6.4 million across 5 years, with a median of -$5.3 million in 2023.
- Annual changes were most pronounced in 2023 — Free Cash Flow jumped 67.51% — and 2026, when it tumbled 96.24%.
- iBio's Free Cash Flow stood at -$10.6 million in 2022, then jumped by 55.56% to -$4.7 million in 2023, then climbed by 17.42% to -$3.9 million in 2024, then tumbled by 47.99% to -$5.8 million in 2025, then decreased by 6.26% to -$6.1 million in 2026.
- Business Quant data shows IBIO's Free Cash Flow at -$6.1 million in Q1 2026, -$5.8 million in Q4 2025, and -$5.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | iBio | 172.22 Mn | 172.22 Mn | - | -6.11 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.11 Mn |
| Mar 31, 2026 | -6.11 Mn |
| Dec 31, 2025 | -5.75 Mn |
| Dec 31, 2025 | -5.75 Mn |
| Sep 30, 2025 | -5.70 Mn |
| Sep 30, 2025 | -5.70 Mn |
| Jun 30, 2025 | -4.60 Mn |
| Jun 30, 2025 | -4.60 Mn |
| Mar 31, 2025 | -3.11 Mn |
| Mar 31, 2025 | -3.11 Mn |
| Dec 31, 2024 | -3.89 Mn |
| Dec 31, 2024 | -3.89 Mn |
| Sep 30, 2024 | -3.72 Mn |
| Sep 30, 2024 | -3.72 Mn |
| Jun 30, 2024 | -5.06 Mn |
| Jun 30, 2024 | -5.06 Mn |
| Mar 31, 2024 | -3.65 Mn |
| Mar 31, 2024 | -3.65 Mn |
| Dec 31, 2023 | -4.71 Mn |
| Dec 31, 2023 | -4.71 Mn |